167 related articles for article (PubMed ID: 20616687)
1. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial).
Stalmans P; Delaey C; de Smet MD; van Dijkman E; Pakola S
Retina; 2010; 30(7):1122-7. PubMed ID: 20616687
[TBL] [Abstract][Full Text] [Related]
2. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial.
de Smet MD; Gandorfer A; Stalmans P; Veckeneer M; Feron E; Pakola S; Kampik A
Ophthalmology; 2009 Jul; 116(7):1349-55, 1355.e1-2. PubMed ID: 19447497
[TBL] [Abstract][Full Text] [Related]
3. A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy.
Benz MS; Packo KH; Gonzalez V; Pakola S; Bezner D; Haller JA; Schwartz SD
Ophthalmology; 2010 Apr; 117(4):791-7. PubMed ID: 20138368
[TBL] [Abstract][Full Text] [Related]
4. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
[TBL] [Abstract][Full Text] [Related]
5. EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG Substudy.
Birch DG; Benz MS; Miller DM; Antoszyk AN; Markoff J; Kozma P; Meunier E; Sergott RC;
Retina; 2018 Feb; 38(2):364-378. PubMed ID: 28198785
[TBL] [Abstract][Full Text] [Related]
6. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
[TBL] [Abstract][Full Text] [Related]
7. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin.
Jackson TL; Regillo CD; Girach A; Dugel PU;
Ophthalmic Surg Lasers Imaging Retina; 2016 Aug; 47(8):716-23. PubMed ID: 27548448
[TBL] [Abstract][Full Text] [Related]
8. Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration.
Novack RL; Staurenghi G; Girach A; Narendran N; Tolentino M
Ophthalmology; 2015 Apr; 122(4):796-802. PubMed ID: 25435217
[TBL] [Abstract][Full Text] [Related]
9. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
Stalmans P; Benz MS; Gandorfer A; Kampik A; Girach A; Pakola S; Haller JA;
N Engl J Med; 2012 Aug; 367(7):606-15. PubMed ID: 22894573
[TBL] [Abstract][Full Text] [Related]
10. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
[TBL] [Abstract][Full Text] [Related]
11. Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.
Varma R; Haller JA; Kaiser PK
JAMA Ophthalmol; 2015 Sep; 133(9):997-1004. PubMed ID: 26068086
[TBL] [Abstract][Full Text] [Related]
12. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ;
Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816
[TBL] [Abstract][Full Text] [Related]
13. LONG-TERM OUTCOMES IN PATIENTS WITH VITREOMACULAR TRACTION TREATED WITH A SINGLE INTRAVITREAL INJECTION OF OCRIPLASMIN.
Tyler L; Singer M; Bell D
Retin Cases Brief Rep; 2017 Winter; 11(1):34-37. PubMed ID: 26849382
[TBL] [Abstract][Full Text] [Related]
14. Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis.
Thomas AS; Folgar FA; Jaffe GJ; Toth CA; Mahmoud TH
Ophthalmol Retina; 2019 Jan; 3(1):42-52. PubMed ID: 30929816
[TBL] [Abstract][Full Text] [Related]
15. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
[TBL] [Abstract][Full Text] [Related]
16. THE OASIS MP-1 SUBSTUDY: Characterization of the Effect of Ocriplasmin on Microperimetry Parameters.
Sadda SR; Dugel PU; Gonzalez VH; Meunier E; Kozma P
Retina; 2019 Feb; 39(2):319-330. PubMed ID: 29206755
[TBL] [Abstract][Full Text] [Related]
17. Effect of ocriplasmin on the management of macular holes: assessment of the clinical relevance of ocriplasmin.
Moisseiev J; Moroz I; Katz G
JAMA Ophthalmol; 2014 Jun; 132(6):709-13. PubMed ID: 24723009
[TBL] [Abstract][Full Text] [Related]
18. [Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin].
Lommatzsch AP; Gutfleisch M; Dietzel M; Heimes B; Spital G; Böhme M; Bornfeld N; Pauleikhoff D
Klin Monbl Augenheilkd; 2014 Sep; 231(9):909-14. PubMed ID: 24788606
[TBL] [Abstract][Full Text] [Related]
19. Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.
Stalmans P; Duker JS; Kaiser PK; Heier JS; Dugel PU; Gandorfer A; Sebag J; Haller JA
Retina; 2013; 33(10):2003-11. PubMed ID: 23881226
[TBL] [Abstract][Full Text] [Related]
20. Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole.
Jackson TL; Verstraeten T; Duchateau L; Lescrauwaet B
Acta Ophthalmol; 2017 Dec; 95(8):e740-e745. PubMed ID: 28133919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
